Eli Lilly and Co

Halozyme Therapeutics announces argenx has nominated four new targets for ENHANZE® drug delivery tech, bringing the total to six, including FcRn. argenx to pay Halozyme $30 million upfront and potential future milestone payments up to $85 million per target.

The FDA's approval of Cobenfy (KarXT) marks a significant milestone in psychopharmacology as the first antipsychotic not targeting dopamine 2 receptors. The drug's journey began with xanomeline, synthesized by Novo Nordisk in the 1980s, showing promise in Alzheimer's and schizophrenia studies but shelved by Eli Lilly. Resurrected by Steven M. Paul, MD, who combined it with trospium at Karuna, the drug's approval highlights the industry's potential lapses in foresight and unnecessary delays in bringing effective treatments to market.

The article discusses the importance of summarizing content accurately and concisely, focusing on retaining original expressions while ensuring clarity.

Tirzepatide and semaglutide outperform other FDA-approved drugs for weight loss, according to a network meta-analysis in 'Obesity'. Tirzepatide 15 mg and semaglutide 2.4 mg showed superior efficacy with no significantly higher risk of adverse events.

The global immunomodulators market is projected to grow from $317.06 billion in 2024 to $1,237.66 billion by 2034, driven by their use in treating autoimmune diseases, cancer, preventing infections, and managing organ transplant rejection. Key factors include advancements in precision medicine, regional growth in Asia-Pacific, and recent acquisitions and partnerships in the sector.

Eli Lilly commits $4.5 billion for a new facility, Lilly Medicine Foundry, in Lebanon, Indiana, to innovate drug production and scale up manufacturing for clinical trials. The site, expected to open in 2027, will support various types of medicines and transfer new technologies to other sites for full-scale production. Indiana is providing infrastructure improvements and economic incentives, aiming to create 400 full-time jobs.

Kurma Partners raised EUR 140 million in the first closing of Biofund IV, targeting EUR 250 million total. The fund aims for 16-20 new investments, focusing on innovative therapeutics. Three initial investments have been made, and the fund leverages Kurma's networks for success.

Eli Lilly to invest $4.5 billion in Lilly Medicine Foundry, combining research and manufacturing in Lebanon, IN, adding 400 jobs by 2027. Total investment at the site will exceed $13 billion.

Eli Lilly invests $4.5bn in Lilly Medicine Foundry, a facility in Indiana’s LEAP district, to integrate advanced manufacturing with drug development, enhancing clinical trial medicine production and exploring manufacturing solutions.